<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8083">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858702</url>
  </required_header>
  <id_info>
    <org_study_id>OLM004-071</org_study_id>
    <nct_id>NCT00858702</nct_id>
  </id_info>
  <brief_title>Calcium Channel Blockers (CCBs) or Diuretics as an Add-on to Olmesartan Medoxomil in Hypertension</brief_title>
  <official_title>Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to test the efficacy and safety of the combination of Calcium
      Channel Blockers (CCBs)(of the dihydropyridine class) or Diuretics (of the thiazide class)
      and olmesartan medoxomil in essential hypertensive patients whose blood pressure is not
      adequately controlled with olmesartan medoxomil alone
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85</measure>
    <time_frame>Baseline to week 8</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)</measure>
    <time_frame>At week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)</measure>
    <time_frame>At week 8</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil tablets and a CCB tablet (of the dihydropyridine class), once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil and a diuretic tablet (of the thiazide class)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil and a CCB</intervention_name>
    <description>olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil and a diuretic</intervention_name>
    <description>olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean seated blood pressure greater than or equal to 140/90 mmHg under circumstances
             in pre-treatment with olmesartan medoxomil

          -  Mean 24-hour blood pressure evaluated by ambulatory blood pressure monitoring greater
             than or equal to 135/80 mmHg under circumstances in pre-treatment with olmesartan
             medoxomil

        Exclusion Criteria:

          -  Patients with secondary hypertension

          -  Any serious disorder which may limit the ability to evaluate the efficacy or safety
             of the test drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Research and Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo Co., Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <lastchanged_date>September 18, 2009</lastchanged_date>
  <firstreceived_date>March 9, 2009</firstreceived_date>
  <firstreceived_results_date>July 16, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Yoshihiro Kakehi</name_title>
    <organization>Daiichi Sankyo Co., Ltd.</organization>
  </responsible_party>
  <keyword>Essential hypertension</keyword>
  <keyword>Combination therapy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium Channel Blockers</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 172 patients were enrolled at 5 centers in Japan from February 12, 2005 to April 30, 2005.</recruitment_details>
      <pre_assignment_details>After the 4 to 6 weeks of olmesartan medoxomil monotherapy period, 105 patients who met the entry criteria for the combination therapy period were randomized to calcium channel blocker (of the dihydropyridine class) combination group or diuretic (of the thiazide class)combination group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
          <description>olmesartan medoxomil tablets and a calcium channel blocker tablet (of the dihydropyridine class), once daily for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Olmesartan Medoxomil Tablets and a Diuretic Tablet</title>
          <description>olmesartan medoxomil tablets and a diuretic tablet (of the thiazide class)once daily for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
          <description>olmesartan medoxomil tablets and a calcium channel blocker tablet, once daily for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Olmesartan Medoxomil Tablets and a Diuretic</title>
          <description>olmesartan medoxomil tablets and a diuretic once daily for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.2" spread="11.2"/>
                <measurement group_id="B2" value="57.4" spread="9.4"/>
                <measurement group_id="B3" value="56.8" spread="10.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="42"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="32"/>
                <measurement group_id="B3" value="63"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Japanese</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Japan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="53"/>
                <measurement group_id="B2" value="52"/>
                <measurement group_id="B3" value="105"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85</title>
        <time_frame>Baseline to week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Primary analysis was conducted for full analysis set. It excluded the patients who were not administrated study drugs, or did not satisfy entry criteria, or had no data after randomisation.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
            <description>olmesartan medoxomil tablets and a calcium channel blocker tablet (of the dihydropyridine class), once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan Medoxomil Tablets and a Diuretic</title>
            <description>olmesartan medoxomil tablets and a diuretic tablet (of the thiazide class) once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="50"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85</title>
            <units>Percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="34.0"/>
                  <measurement group_id="O2" value="59.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0158</p_value>
            <p_value_desc>No consideration for multiplicity</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)</title>
        <description>Drug-related adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence.</description>
        <time_frame>At week 8</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety analysis (Clinical AEs:subjective symptoms / objective findings) was conducted for Safety Population. It excluded the patients who were not administrated study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
            <description>olmesartan medoxomil tablets and a calcium channel blocker (of the dihydropyridine class) tablet, once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan Medoxomil Tablets and a Diuretic</title>
            <description>olmesartan medoxomil tablets and a diuretic tablet (of the thiazide class) once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)</title>
            <description>Drug-related adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence.</description>
            <units>Percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="7.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>0.0566</p_value>
            <p_value_desc>No consideration for multiplicity</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)</title>
        <description>Drug-related, laboratory value change adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence.</description>
        <time_frame>At week 8</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety analysis (laboratory AEs:abnormal changes in clinical laboratory values) was conducted for Safety Population. It excluded the patients who were not administered study drugs, or had no clinical laboratory data.</population>
        <group_list>
          <group group_id="O1">
            <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
            <description>olmesartan medoxomil tablets and a calcium channel blocker tablet (of the dihydropyridine class), once daily for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olmesartan Medoxomil Tablets and a Diuretic</title>
            <description>olmesartan medoxomil tablets and a diuretic tablet(of the the thiazide class) once daily for 8 weeks</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)</title>
            <description>Drug-related, laboratory value change adverse events are adverse events(AEs) as determined by the Investigator that can not be denied to be related to the study drugs. The relationship between adverse events and drugs were determined by the Investigator based on his/her clinical judgement. Factors used in determining relatedness included, but are not limited to, the medical history of the participant, use of concomitant medication, and the time course from drug administration to AE occurence.</description>
            <units>Percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.9"/>
                  <measurement group_id="O2" value="44.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>No consideration for multiplicity</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Olmesartan Tablets and a Calcium Channel Blocker Tablet</title>
          <description>olmesartan medoxomil tablets and a calcium channel blocker tablet, once daily for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Olmesartan Medoxomil Tablets and a Diuretic</title>
          <description>olmesartan medoxomil tablets and a diuretic once daily for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1"/>
                <counts group_id="E2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1"/>
                <counts group_id="E2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
